Celgene
NICE recommends Celgene’s REVLIMID for multiple myeloma
January 27, 2021Research and Development Cancer, Celgene
NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment after an autologous stem cell …
NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant
September 11, 2020Medical Communications, Sales and Marketing Celgene, NICE, Revlimid
It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance of newly diagnosed multiple myeloma …
NICE recommends Celgene’s Revlimid combo for follicular lymphoma
February 27, 2020Sales and Marketing Cancer, Celgene, NICE, Revlimid, follicular lymphoma, pharma
NICE has chosen to recommend Celgene’s Revlimid (lenalidomide) for use on the NHS, it has emerged, alongside Genentech’s Rituxan (rituximab), …
Celgene and Acceleron’s Reblozyl secures FDA approval for anaemia in beta thalassaemia
November 11, 2019Sales and Marketing Acceleron, Celgene, Reblozyl, beta thalassaemia, pharma
The FDA has moved to authorise Celgene and Acceleron Pharma’s Reblozyl (luspatercept-aamt) in the treatment of anaemia associated with the …
Celgene signs $1.5bn partnership with Immatics to fight cancer with engineered T-cell therapies
August 29, 2019Research and Development Cancer, Celgene, immatics, immunotherapy, pharma
Celgene and biopharma firm Immatics Biotechnologies have announced that they have entered a partnership valued at a potential $1.5 billion …
Celgene’s Otezla becomes first and only FDA-approved therapy for oral ulcers in Behçet’s Disease
July 22, 2019Sales and Marketing Behçet's disease, Behçet’s Disease, Celgene, apremilast, otezla, pharma
Celgene has revealed the US approval of Otezla (apremilast), confirming that the FDA awarded marketing authorisation for the treatment of …
Bristol-Myers Squibb to sell off Celgene’s Otezla ahead of $74 billion merger
June 24, 2019Manufacturing and Production Bristol-Myers Squibb, Celgene, FTC, otezla, pharma, psoriasis
Bristol-Myers Squibb has agreed to sell off Celgene’s psoriasis treatment Otezla, to appease antitrust regulators. BMS will divest one of …
FDA first as agency expands label on Celgene’s Revlimid in previously treated follicular or marginal zone lymphoma
May 29, 2019Research and Development, Sales and Marketing Cancer, Celgene, FDA, Revlimid, lymphoma, pharma
Celgene has revealed that the FDA has expanded its authorised indications of Revlimid (lenalidomide) to include combination with a rituximab …
NICE recommends Celgene’s Revlimid in treatment-naive multiple myeloma
May 20, 2019Sales and Marketing Celgene, NICE, Revlimid, UK, multiple myeloma
Celgene’s Revlimid (lenalidomide) has been recommended by NICE for use on the NHS in England and Wales in combination with …
Sorrento Therapeutics seek $1 billion from billionaire biotech investor Patrick Soon-Shiong
April 4, 2019Business Services, Sales and Marketing Abraxane, Celgene, Cynviloq, Patrick Soon-Shiong, Sorrento, lawsuits
Sorrento Therapeutics is seeking $1 billion in damages from billionaire biotech investor Patrick Soon-Shiong, owner of US newspaper the LA …
Celgene inks drug discovery deal worth at least £25m with AI firm Exscientia
March 21, 2019Research and Development Celgene, Exscientia, drug discovery, pharma
Celgene has entered into a new three-year partnership with British artificial intelligence and drug discovery firm Exscientia to the value …
Celgene’s Abraxane combo flops in phase 3 cancer trials
March 14, 2019Research and Development Abraxane, Celgene, clinical trials, pharma, trials
Celgene’s Abraxane, in combination gemcitabine, has failed to meet its primary endpoint in a pivotal Phase 3 trial of patients …
Disapproval from top shareholder throws $74bn BMS/Celgene merger into doubt
February 28, 2019Sales and Marketing Bristol-Myers Squibb, Celgene, acquisition, pharma
The news kicked off 2009 with a bang when Bristol-Myers Squibb announced it intended to acquire Celgene for $74 billion, …
Top Ten most popular articles on Pharmafile.com this week!
January 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Celgene, NHS, health, pharma, venlytxo
While American firm AbbVie gained approval for leukaemia drug Venlytxo, the NHS defeated the US multinational thus week in court, …
Celgene signs deals with two Massachusetts-based biotechs
January 21, 2019Sales and Marketing Celgene, Kyn, Obsidian, cell therapy, immuno oncology, immuno-oncology
New Jersey-based biotechnology firm Celgene has signed deals with two Massachusetts-based biotechs: immuno-oncology specialist Kyn therapeutics and cell therapy firm …
Latest content
FibroFind appoints Lee Borthwick as CEO
